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Abstract We review the current state of knowledge of
remyelination in multiple sclerosis (MS), concentrating on
advances in the understanding of the pathology and the
regenerative response, and we summarise progress on the
development of new therapies to enhance remyelination
aimed at reducing progressive accumulation of disability in
MS. We discuss key target pathways identified in experi-
mental models, as although most identified targets have not
yet progressed to the stage of being tested in human clinical
trials, they may provide treatment strategies for demye-
linating diseases in the future. Finally, we discuss some of
the problems associated with testing this class of drugs,
where they might fit into the therapeutic arsenal and the
gaps in our knowledge.
1 Introduction
Multiple sclerosis (MS) is the most common cause of non-
traumatic disability in young people, affecting approxi-
mately 2.5 million people worldwide [1]. Despite much
research effort, the aetiology is not fully understood, and
may include genetic susceptibility, epigenetic regulation
and environmental factors [2]. MS is a disease of the
central nervous system (CNS), and therefore neurological
impairment can include visual, motor, sensory, coordina-
tion or cognitive deficits depending on the site of damage
[3, 4]. Most patients initially present with relapsing-
remitting disease (RRMS), where periods of symptomatic
impairment are followed by recovery. This phase can last
for years; however, eventually most patients will progress
to a secondary progressive (SPMS) disease course, where
residual disability gradually accrues over time. Some
patients steadily accumulate disability with no recovery
from the very onset of MS; this is known as primary pro-
gressive MS (PPMS).
These different phases of the disease reflect the under-
lying pathology, which is at first more inflammatory and
demyelinating (in the relapsing and remitting phase) and
then more neurodegenerative (in the progressive phase).
Currently licensed disease-modifying drugs for MS are
anti-inflammatory; they suppress the immune system and
reduce relapse rates but are ineffective in progressive dis-
ease. There are as yet no progressive disease-modifying
drugs to slow, stop or reverse neurodegeneration. Neuro-
protective drugs have been sought for many other neuro-
logical diseases, including stroke, spinal cord injury and
Alzheimer’s disease, with limited success. However, an
alternative strategy is available in MS, where neuropro-
tection may be enhanced through myelin repair—remye-
lination. In this review, we outline the recent advances
made in our understanding of how myelin is lost in MS,
what prevents remyelination in humans from being effi-
cient, and how we might be able to manipulate remyeli-
nation to enhance it to treat progressive MS.
2 Pathology of Multiple Sclerosis
The pathological hallmarks of all MS subtypes are focal
areas or ‘plaques’ of demyelination in the CNS, with sur-
rounding inflammation and neurodegeneration. Two
hypotheses aim to explain the underlying pathology of MS:
first, that inflammation induces demyelination, which leads
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to secondary axon degeneration; or second, that MS is a
neurodegenerative disease with secondary inflammation
and demyelination.
Classically, MS has been thought of as an autoimmune
disease. Self-antigens (as yet mostly unknown) presented
by major histocompatibility complex class II antigen-pre-
senting cells (e.g. dendritic cells and macrophages) are
misidentified as being foreign and there is activation of
auto-reactive T cells [5, 6]. These auto-reactive T cells
cross the blood–brain barrier, and cause inflammatory
damage through expression of inflammatory cytokines and
reactive oxygen species and attraction of other immune
cells like macrophages and B cells, creating a loop of pro-
inflammatory enhancement, which causes demyelination
and axonal degeneration. In MS, transient gadolinium-
enhancing brain lesions are seen on magnetic resonance
imaging (MRI), confirming blood-brain barrier breakdown,
and oligoclonal immunoglobulin G (IgG) bands are seen in
the cerebrospinal fluid (CSF) (but not the serum), sugges-
tive of a B-cell response to antigens within the CNS [7].
Demyelination of axons removes saltatory conduction,
physical protection and metabolic support [8, 9] of the
axon and causes neurodegeneration. Supporting this, more
axonal damage is seen in lesions with a high degree of
acute inflammation [10, 11] and is also a consequence of
chronic demyelination [12, 13]. However, histopatholo-
gical analysis of post mortem brains from MS patients also
shows that axonal damage occurs not just in active
demyelinating lesions but can also be present in lesions that
show signs of remyelination [14]. In addition, axonal injury
is already extensive in early stages of the disease and
decreases with time [15], and this is supported by the
coexistence of inflammatory and neurodegenerative bio-
markers early in MS [16].
Therefore, is MS instead primarily a neurodegenerative
disease? In MS, there are widespread grey matter lesions
showing signs of neurodegeneration but less immune cell
infiltration and demyelination than in white matter lesions
[17], and the load of cortical grey matter lesions correlates
with changes suggesting diffuse axonal loss in normal-
appearing white matter of MS patients detected on MR
sequences [18]. Neurodegeneration occurs early and in
widespread areas of the brain distant from white matter
lesions [19]. The extent of neurodegeneration also does not
always correlate with the amount of demyelination—for
example, there is more axonal loss in spinal cord plaques
from patients with PPMS than in those from patients with
SPMS, despite more extensive demyelination in SPMS
patients [20]. Furthermore, progressive disability correlates
more with neurodegeneration (and brain atrophy) than
white matter demyelination [21, 22].
Whatever the order of pathological events, it is clear that
preventing inflammation, demyelination and
neurodegeneration, or enhancing remyelination and neuro-
protection, are all potential targets for therapies to reduce
disease and disability in MS. Licensed drugs that are
effective at reducing inflammation and demyelination in
MS are now available, but no therapies exist to reduce, stop
or reverse neurodegeneration. Regardless of whether axonal
loss is the primary event or occurs secondary in the disease
pathology of MS, it is a major contributor to accumulation
of permanent disability [23] and it is untreatable. There are
two ways to approach neuroprotective therapy in MS—
either to use agents to directly protect axons, or to improve
remyelination, which restores the support of axons.
3 How Does Remyelination Mediate Neuroprotection?
Myelin is formed by oligodendrocytes in the CNS by
extension and wrapping of their plasma membrane pro-
cesses around neuronal axons in a spiral fashion. Each axon
has multiple short segments of myelin (internodes) that are
separated by gaps (nodes of Ranvier), where sodium
channels are concentrated and which facilitate fast saltatory
nerve conduction. As well as providing an electrical insu-
lating sheath, oligodendrocytes provide the axons with
metabolic support via channels within the myelin [8, 9].
Therefore, demyelination leads to both decreased nerve
conduction velocity, resulting in neurological impairment,
and predisposition of the axons to neurodegeneration of the
axons to neurodegeneration due to lack of physical and
metabolic support. Demyelinated axons may also have a
higher metabolic demand, as electrogenic machinery along
the axons, such as sodium channels, no longer cluster at the
nodes of Ranvier, and nerve impulse conduction becomes
less efficient [24, 25]. If this increased metabolic demand is
not met by mitochondria, which also have to reorganise in
a demyelinated axon, the production of nitric oxide is
thought to further compromise axonal integrity [26, 27].
This hypothesis is supported by the fact that in MS brain,
axonal degeneration is most prevalent in actively demye-
linating lesions where inflammation is greatest, and that
sodium channels in these areas are found diffusely located
along demyelinated axons [28].
Remyelination may reverse or prevent some of these
structural and metabolic changes observed in axons after
demyelination. Studies in rodent models of MS using
toxin-mediated demyelination showed that remyelinating
cells were able to restore the normal pattern of electrogenic
machinery, in particular, clustering of sodium channels in
nodes of Ranvier and potassium channels in the juxtapa-
ranode [29]. Furthermore, increases in mitochondrial con-
tent and clustering of nodal proteins were found in
remyelinated but not demyelinated axons in human and
rodent tissues, suggesting that remyelination can also
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restore metabolic changes that occur when axons are
demyelinated [30, 31]. Neuroprotection through remyelina-
tion has been explored in a mouse model of experimental
demyelination, in which oligodendrocyte precursor cells
with the capacity to remyelinate were killed by irradiation
and this resulted in reduced myelin repair and increased
axonal loss. However, transplantation of neural progenitor
cells into the irradiated and demyelinated area rescued both
remyelination and axonal survival [32]. Moreover, CNS
remyelination in various experimental animal models is
associated with functional recovery [33–35]. Studies in
humans to support these findings in rodents are difficult, as
remyelination is difficult to measure at high resolution
in vivo, but there is supportive evidence from post mortem
MS patient brain tissue studies that shows that remyelina-
tion can be extensive in subsets of MS patients [36], and
remyelinated lesions exhibit less acute axonal injury than
active demyelinating lesions [15].
However, perhaps remyelination is not sufficient to fully
prevent axonal loss. We know that internodal lengths are
shorter in remyelinated axons (resulting in more sodium
channel clusters per length of nerve) and that mitochondrial
changes are not fully reversed [31]. There is also no doubt
that axonal degeneration can occur without areas of
demyelination (for example, see Bitsch et al. [14]), and this
could be either through a separate mechanism or perhaps
through related anterograde and retrograde degeneration of
axons damaged in a demyelinated plaque. Direct inflam-
matory damage by activated macrophages and microglia
may also occur, as these have also been found outside of
active lesions in the normal-appearing white matter in the
CNS [37]. The question of whether remyelination can
protect axons long term was asked in a mouse model of
demyelination using the toxin cuprizone, where there was
full remyelination and functional recovery initially, but a
late functional decline, concurrent with axonal loss in
affected white matter tracts and changes in myelin com-
position [38]. However, cuprizone also damages axons
[39], which may well have contributed to these changes.
Therefore, the debate still exists on whether remyeli-
nation completely restores normal axonal health and pre-
vents neurodegeneration. However, it does appear to
restore much function and at least limit degeneration, and
so enhancing this process has become a key therapeutic
aim in MS, to try and avoid or treat progressive disease.
4 The Steps Necessary for Remyelination
To develop a therapy to enhance remyelination requires
knowledge of the biology involved. Myelinating oligo-
dendrocytes during development originate from oligoden-
drocyte precursor cells (OPCs). OPCs are still present in
the brain parenchyma and in progenitor zones in the mature
adult CNS and are the source of oligodendrocytes that
mediate remyelination of demyelinated axons [40], coming
either from within the lesion or from the immediately
surrounding white matter [41], or from the subventricular
zone (the site of neurogenesis in the adult brain), if the
lesion site is in close proximity [42, 43]. This population of
progenitor cells is likely responsible for generating almost
all remyelinating cells in demyelinating lesions in the adult
CNS according to fate mapping of OPCs in mice [44]. Pre-
existing mature oligodendrocytes are unlikely to contribute
to remyelination, either directly or by de- and re-differen-
tiating (similarly to Schwann cells in the peripheral ner-
vous system [PNS] [45]), as previous studies have reported
a lack of remyelination capacity of post-mitotic oligoden-
drocytes, even if they survive within a demyelinated lesion
or are transplanted from a normally myelinating area into a
lesion site [46, 47]. Conversely, rat OPCs transplanted into
demyelinated areas can differentiate into myelinating oli-
godendrocytes and produce robust myelin [48]. Further-
more, dividing endogenous progenitor cells in the adult rat
brain have been shown to respond to demyelination by
differentiating into myelin-forming oligodendrocytes [49].
In early stages of MS, spontaneous remyelination does
occur, and it can be reasonably extensive in some patients
[36, 50], but this declines with age [51]. For successful
remyelination to take place, OPCs need to be able to
respond to demyelination by proliferation, migration to the
lesion site, differentiation and ensheathment of axons (as
described in Fig. 1). Deficient remyelination can therefore
occur through a failure at any of these steps. From study of
post mortem MS brain, it has been estimated that around
70 % of MS lesions that remain demyelinated contain
plentiful OPCs, suggesting a failure of differentiation and
the other 30 % contain few or no OPCs, indicating failure
of recruitment [3, 52]. Therefore, manipulations to improve
either or both of these processes may be beneficial for
remyelination. The process of remyelination does not
solely involve oligodendroglial cells, and, increasingly,
other cells in the vicinity are being implicated. Microglia/
macrophages are needed to clear myelin debris following
demyelination, which is known to be inhibitory for
remyelination, at least in rodents [53], and secrete sub-
stances to create a favourable environment for precursor cell
maturation and remyelination [54]. Astrocytes have also
been implicated in both providing useful factors for
remyelination and impeding it, with astrocytic scarring [55].
To test ways of manipulating and improving remyeli-
nation, we use animal models, mostly in rodents. However,
most animal models of demyelination show a robust and
complete remyelination response, and so to this extent they
poorly model humans, where remyelination capacity is
limited. Although myelin is replaced around virtually all
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axons after demyelination in rodents, remyelinated myelin
sheaths are not fully restored to normal, as they are thinner
and with shorter internodal lengths compared with devel-
opmental myelin sheaths in both rodents and humans
[56–60]. In spite of this, remyelinated axons do conduct
electricity using saltatory conduction, albeit at a somewhat
slower velocity, but this seems sufficient to restore function
in animal models [33–35].
5 Promoting Remyelination—Potential Candidate
Drugs
How can we intervene to improve remyelination and
maintain function in MS patients? All current treatments
used to treat MS in clinical practice act primarily on mod-
ulating or suppressing the immune system to prevent further
relapses, but they do not delay or slow disease progression
or affect remyelination. The current licensed treatments (in
the UK) are the beta-interferons, glatiramer acetate, natal-
izumab and fingolimod. Natalizumab (a monoclonal anti-
body blocking a4 integrin and preventing T cells from
crossing the blood–brain barrier) and fingolimod (a sphin-
gosine-1-phosphate receptor modulator preventing T cells
from exiting lymph nodes) are both also in clinical trial to
test whether they prevent or slow progression of disease
(NCT01416181, NCT00731692), but they are not being
directly tested for their ability to promote remyelination.
Fingolimod does promote rodent oligodendrocyte process
extension and survival in vitro [61, 62]; however, it remains
unclear how it affects regeneration of myelin, as although
increased remyelination has been demonstrated in the
multi-cellular environment of ex vivo rodent slice culture
preparations [63], it was not seen in in vivo rodent studies
[64]. While one human clinical trial has reported no effect
of fingolimod on disease progression in RRMS patients
[65], other trials continue (NCT00731692, NCT01498887).
The wealth of other drugs designed to reduce MS relapses
(including daclizumab, teriflunomide, ocrelizumab, laqu-
inimod and siponimod), which are in clinical trial, awaiting
licensing, or that have received licensing in some countries,
have also not been shown to affect disease progression or
remyelination. However, alemtuzumab (now approved by
the European Medicines Agency) and dimethyl fumarate/
BG-12 (approved in Europe and the USA) do appear to have
an effect on reducing disease progression as outlined below.
Furthermore, clinical trials have started with anti-LINGO-1
antibodies and the human monoclonal IgM antibody num-
ber 22, which have been designed to enhance remyelination.
5.1 Alemtuzumab
Alemtuzumab is a monoclonal antibody that destroys
lymphocytes via CD-52 recognition and is currently used
in the treatment of T-cell lymphoma and chronic lymphatic
leukaemia [66, 67]. Two randomised controlled phase III
clinical trials investigating the efficacy of alemtuzumab
Fig. 1 Major steps required for remyelination. For successful
remyelination, oligodendrocyte precursor cells need to be recruited
to the lesion site and then differentiate into myelinating oligoden-
drocytes. This is a very intricate process that can fail if not regulated
effectively
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compared with interferon-beta 1a in patients who had not
received other primary treatment (CARE-MS I [Compari-
son of Alemtuzumab and Rebif Efficacy in Multiple
Sclerosis]) and who had failed on other disease-modifying
medication (CARE-MS II) were recently completed. Both
trials showed that patients on alemtuzumab treatment were
less likely to experience a relapse over the course of the
2 years [68, 69]. In addition, patients treated with ale-
mtuzumab in CARE-MS II (only) showed a 42 % reduc-
tion in sustained accumulation of disability. The
mechanism for this reduction in disability progression may
be directly related to fewer damaging episodes of demye-
lination, or indirectly allowing more time for remyelination
to occur spontaneously, or directly by an effect on neuro-
protection/remyelination. One possible support for the
latter is that cultures of peripheral blood mononuclear cell
cultures, in particular T cells, produce increased concen-
trations of potentially useful neuronal growth factors when
treated with alemtuzumab and stimulated with myelin basic
protein. In addition, media from these cell cultures promote
survival of neurons and OPCs and enhance oligodendro-
cyte differentiation and myelination [70]. Future clinical
trials are planned using MRI analysis to measure myelin
repair for further exploration of the putative neuroprotec-
tive and remyelinating potential of alemtuzumab
(NCT01307332, NCT01395316).
5.2 Dimethyl Fumarate
Dimethyl fumarate is the methyl ester of fumaric acid and
has recently been approved by the US Food and Drug
Administration (FDA) and European Medicines Agency
for treatment of MS. It is both immunomodulatory and
upregulates the transcription factor Nrf2 [71], but its pre-
cise mode of function is unknown. Newly completed phase
III clinical studies have indicated its ability to significantly
reduce relapse rate and development of brain lesions in
patients with RRMS [72, 73]. In addition, these trials
showed a reduced risk of disability progression at 2 years
and a favourable safety and tolerability profile. However,
while there is no direct evidence that dimethyl fumarate
has effects on remyelination and neuroprotection in either
humans or experimental models of MS, the related anti-
psychotic compound quetiapine, a fumarate salt, does
possess pro-remyelination and neuroprotective properties
in rodents [74]. There is an increase in differentiation of
rodent progenitor cells into oligodendrocytes and a greater
extent of myelination in cortical aggregate cultures after
treatment with quetiapine [75]. Moreover, findings from
in vivo experimental models demonstrate reduced demye-
lination and loss of oligodendrocytes [76, 77] with que-
tiapine treatment, as well as faster return of myelin proteins
[78]. These data suggest that quetiapine enhances
remyelination in experimental models, raising hopeful
possibilities for the related compound dimethyl fumarate in
humans.
5.3 Anti-LINGO-1 Antibodies
LINGO-1 is a protein containing N-terminal leucine-rich
repeat domains that interacts with the Nogo receptor and
has been shown to regulate axon outgrowth [79]. Recent
research revealed that LINGO-1 plays a key role in nega-
tively regulating OPC differentiation and remyelination in
rodent models of MS; therefore, blocking this may be
effective in promoting remyelination in the clinical setting.
LINGO-1 gene knockout in mice, or treatment with an
anti-LINGO-1 antagonist antibody, resulted in enhanced
functional recovery from inflammatory autoimmune
demyelination and also increased remyelination [80].
Similarly, the anti-LINGO-1 antagonist also showed
increased remyelination in toxin-induced demyelinating
lesions in rats, by direct stimulation of OPC differentiation
[81, 82]. A recent preclinical study in an immune model of
demyelination in rats (MOG-EAE), thus far only published
in abstract form, also demonstrates a fivefold reduction of
axonal loss in the optic nerve of rats treated with BIIB033
(an anti-LINGO-1 antibody) compared with control anti-
body, which became more marked (eightfold reduction) in
combination with methylprednisolone [83]. A clinical
phase Ib study compared the effect of BIIB033 (an anti-
LINGO-1 antibody) in patients with RRMS in a placebo-
controlled randomised trial (NCT01244139); this is the first
trial targeted at directly improving remyelination in MS.
The study was completed in April 2012, showing no seri-
ous adverse events, as reported at the American Academy
of Neurology annual meeting. A phase II trial is planned
and will give additional information with regards to safety,
tolerability and efficacy (NCT01864148).
5.4 Human Monoclonal IgM Antibody 22
The human monoclonal IgM antibody 22 (rHIgM22) was
initially discovered in the Mayo Clinic (Rochester, MN,
USA), where researchers found that this recombinant
antibody, usually present in the serum of human MS
patients, was able to induce spinal cord remyelination in a
virus-mediated mouse model of demyelinating disease
[84]. Compared with control-treated animals, mice that
received rHIgM22 exhibited fewer lesions (34.3 % [rHI-
gM22] vs. 41.8 % [control]) and increased remyelination
(59.7 % [rHIgM22] vs. 15.8 % [control]). Similar increa-
ses in remyelination were reported in MRI studies using the
same experimental animal model [85]. Further research
suggests that this pro-remyelination effect of rHIgM22 is
independent of immunomodulation [86] and is associated
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with anti-apoptotic signalling in pre-myelinating oligo-
dendrocytes [87]. Recent data provide evidence of potential
mechanisms underpinning the remyelination-enhancing
effect of rHIgM22, involving the Src family kinase Lyn
and platelet-derived growth factor (PDGF)-receptor alpha
signalling [88, 89]. A phase I clinical trial is now recruiting
patients to evaluate safety, tolerability, pharmacokinetics
and immunogenicity of a single intravenous dose of rHI-
gM22 in patients with MS (NCT01803867). This study
may provide a first indication of whether rHIgM22 has
similar pro-myelinating effects in human MS patients. The
estimated end date of the trial is September 2014.
These four compounds, two of which are primarily anti-
inflammatory but may also aid remyelination, and two of
which have been designed to enhance remyelination, are
likely to be the first of many (Fig. 2). LINGO-1 was one
of the first molecules shown to aid remyelination in the
labarotory, in 2007, and is now in clinical trial. Other
molecules that have since been discovered are making their
way in the same direction, and either promote endogenous
remyelination by improving OPC migration or OPC dif-
ferentiation or involve cell transplantation. We discuss a
selected number of interesting candidates below.
6 Pre-Clinical Approaches to Enhancing
Remyelination
6.1 Enhancing Endogenous Remyelination
To enhance endogenous remyelination, research has
therefore focussed on the two essential steps—to repopu-
late the demyelinated area with OPCs and to promote their
remyelinating ability—and several factors/pathways have
already been identified (Fig. 2).
6.1.1 Aiding Migration of Oligodendrocytes
At least 30 % of MS lesions lack OPCs, pointing towards
insufficient OPC recruitment [3, 90]. One research goal has
therefore been to identify targets that will aid the migration
of OPCs to the demyelinated area. PDGFa is the archetypal
chemoattractant for OPCs, although it is difficult to sepa-
rate this effect from its effect on OPC proliferation. OPCs
express the PDGFa receptor, and repopulate the lesion
site during the early remyelination process in successful
remyelination in a mouse model [91]. In a rat model with
toxin-induced demyelination, addition of PDGF increased
both OPC number (mitogenic) and presence in lesions
though with no increases in remyelination [92]. However,
using the same model but with a different delivery system
of PDGF resulted in an increased number of oligodendro-
cytes and enhanced remyelination [93]. Thus, improving
the number of OPCs in the correct place may help, but in
animal models where remyelination is normally robust and
does not appear to fail due to insufficient OPC recruitment,
this may be difficult to ascertain. A link may exist between
PDGF and the human monoclonal IgM (rHIgM22), which
is currently in clinical trial as described above. Evidence
from in vitro studies suggests that activation of the PDGF-
alpha receptor by rHIgM22 is necessary for stimulation of
OPC proliferation and promotion of remyelination [89].
The semaphorins have also been identified as potential
targets to promote OPC recruitment. These are a class of
secreted and transmembrane proteins that were primarily
described as axonal guidance molecules in the developing
nervous system. Class 3 semaphorins have also been
identified as chemotactic factors for oligodendroglial cells
during development. Semaphorin 3A (Sema3A) and 3F
(Sema3F) aid the recruitment of glial precursor cells from
the brain to the developing optic nerve by their repulsive
and attractive properties, respectively [94, 95]. These
molecules are down-regulated in normal brain white matter
but are re-expressed after injury, including demyelination
in rodents and humans [96]. Moreover, expression of the
semaphorin 3 receptors, neuropilins and plexins, is
increased on OPCs after demyelination in mice, and upon
Sema3A/3F overexpression around lesions, OPC recruit-
ment to lesions was reduced or increased, respectively [97].
In human MS post mortem tissue, those lesions expressing
the chemorepellent Sema3A were more likely to contain
few OPCs and not to show remyelination [52]. Further-
more, in a model of focal toxin-induced demyelination in
the mouse corpus callosum, addition of recombinant
Sema3A to the lesion decreased OPC recruitment and
remyelination, and rSema3F addition or use of a Sema3A
Fig. 2 Selected factors that influence remyelination and their mech-
anism of action. Several factors/signalling pathways, which positively
(green) or negatively (red) influence remyelination by altering known
necessary steps during the remyelination process have already been
identified. BMP bone morphogenic proteins, PDGF platelet-derived
growth factor
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knockdown mouse increased OPC recruitment and
remyelination. These results give us two new therapeutic
targets for promotion of remyelination.
Other chemokines that are able to influence immune cell
migration have also been detected around demyelinating
lesions. Omari et al. [98, 99] found that immature and more
mature OPCs expressed chemokine receptors CXCR1-3
in vitro. The respective ligands CXCL8, 1 and 10 were
absent from normal CNS tissue, but were detected in
reactive astrocytes bordering MS lesions, providing possi-
ble cues for OPC recruitment. Overexpression of CXCL1
led to a milder disease course, decreased neurodegenera-
tion and more prominent remyelination in an immune-
mediated mouse model of MS [100], supporting a potential
pro-migratory, pro-myelinating and neuroprotective func-
tion of CXCL1.
Thus, a new group of pro-migratory or anti-repellent
molecules have been generated to be investigated further
for therapies.
6.1.2 Promoting Oligodendrocyte Differentiation
Around 70 % of demyelinated MS lesions contain imma-
ture oligodendroglial cells that appear to be in an arrested
state, unable to fully differentiate [3, 90]. As well as the
LINGO-1 molecule, discussed above, there are now more
than ten targets in this group. These have been identified
either due to their importance in developmental myelina-
tion or from expression screens of demyelinated tissue.
Two pathways known to be important in developmental
myelination are the Notch-1 and Wnt pathways. The
Notch-1 receptor ligand Jagged-1 is expressed by reactive
astrocytes around injury sites and was first identified as a
potential negative regulator of remyelination in a micro-
array screen [101]. During development, Notch–Jagged
signalling inhibits OPC differentiation; with Notch-1-null
oligodendroglial cells exhibiting accelerated oligodendro-
cyte differentiation and myelination [102, 103]. Notch-1
also appears to be a key regulator of remyelination as
Notch-1 and its effector Hes5 are detected in OPCs in
demyelinating lesions in rodent models in vivo, with Notch
signalling hindering OPC maturation and myelin formation
in vitro [104]. Moreover, transforming growth factor
(TGF)-ß, a cytokine upregulated in MS, was able to trigger
Jagged-1 expression in reactive human astrocytes, which
are known to border MS plaques lacking remyelination,
while Notch-1 and the downstream effector gene Hes5
localised to immature oligodendroglial cells [101, 105].
Similarly, the Wnt pathway negatively regulates devel-
opmental myelination. In transgenic mice overexpressing
ß-catenin, a protein complex acting as an intracellular
signal transducer in the Wnt pathway, there is no impair-
ment of embryonic development of oligodendrocytes but
later differentiation is affected, resulting in fewer oligo-
dendrocytes expressing mature myelin markers (PLP) in
the white matter [106]. Consequently, in these mice,
electron microscopic analysis at postnatal day 15 (P15)
showed hypomyelination of axons, which reached normal
wild-type levels by P50, suggesting that Wnt signalling
delays rather than blocks oligodendrocyte maturation.
Similarly, experimental toxin-induced demyelination in
these transgenic mice also resulted in delayed oligoden-
drocyte differentiation during remyelination [118]. Tcf4,
an intranuclear binding partner of ß-catenin that is nor-
mally detected in developing mice but not in adult white
matter, is re-expressed upon white matter demyelination in
adult animals [106, 107]. As Tcf4 locates to OPCs, which
are recruited to the lesion site in experimental models, and
as it is also highly expressed in MS lesions, Tcf4 may also
play a role in regulating oligodendrocyte differentiation
and myelin repair through active Wnt signalling.
A further molecule critical in development is sonic
hedgehog (Shh), which is essential for oligodendrocyte
specification. Studies in the adult brain have shown that
Shh is still expressed in certain areas, for maintenance of
stem cell niches, which show reduced cell proliferation
in vivo if Shh signalling is blocked [108, 109]. Viral
application of Shh into the lateral ventricle of adult mice
results in increased OPC proliferation, with subsequent
differentiation, suggesting that overexpression of Shh
modifies the stem cell niche to increase the production of
precursor cells, which will ultimately differentiate along
the oligodendroglial lineage [110]. In experimental demy-
elinating lesions, Shh upregulation in oligodendroglial cells
results in increased OPC proliferation and a Shh antagonist
impairs myelin repair [111].
To discover new pathways involved, expression screens
have been used. Microarray analysis of demyelinated
lesions from rat brain at different stages of remyelination
identified the nuclear retinoid X receptor (RXR)-c pathway
as a positive regulator of endogenous remyelination [112].
OPCs express this receptor, and treatment of OPCs with an
RXR-c antagonist in vitro leads to impaired OPC matura-
tion, whereas incubation with 9-cis-retinoic acid, a RXR
agonist, stimulates differentiation, myelination and remye-
lination in culture. Furthermore, focal demyelinating
lesions in RXR-c knockout mice show accumulation of
immature oligodendrocyte lineage cells, and treatment of
rats with the RXR-c agonist improves remyelination [112].
Small molecule agonists of this receptor are currently being
sought.
Another screen to identify molecules increased in
inflammation that aid myelination has identified endothelin
2 as a stimulus for remyelination [113]. Endothelin 2
enhances OPC differentiation, and promotes myelination
and remyelination in ex vivo explant cultures. The
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endothelin receptor type B is expressed by rodent and
human oligodendroglial cells [114, 115] and by human
oligodendroglial cells in MS brain lesions. Treatment of
rats with the agonist of this receptor after a focal demye-
linating lesion led to increased remyelination by enhancing
differentiation of oligodendrocytes [119].
Other molecules involved include the chemokine
CXCL12 and its receptor CXCR4, which promote migra-
tion, proliferation and differentiation of neural precursors
and, if inhibited, reduce remyelination [116]. The bone
morphogenic proteins (BMPs) 4, 6 and 7 are up-regulated
in immune-mediated demyelinating lesions in mice [117],
and inhibition of BMP4 increases remyelination in areas of
focal CNS demyelination in mice [118]. However, this
success may also be related to BMP-mediated astrogliosis.
The extracellular matrix protein hyaluronan is expressed in
human MS lesions and, in immune-mediated demyelinated
lesions in mice, hyaluronan blocks OPC differentiation
in vitro and in vivo, and may be mediated through the Toll-
like receptor (TLR)-2, as this receptor is strongly expressed
by oligodendrocytes and TLR2-agonists are able to inhibit
OPC differentiation in vitro [119]. Moreover, neutralising
antibodies of TLR2 have been shown to prevent hyaluro-
nan-mediated failure of OPC differentiation and TLR-null
mice exhibit faster and more effective remyelination.
It is clear even from this selected list that remyelination
is not regulated by one single molecule but instead through
a combination of signalling pathways acting on OPCs and
oligodendrocytes, but also no doubt on the other cell
players, the microglia/macrophage, astrocytes and even the
blood vessels. There is much to understand about this
pathology and regenerative response, but at least the cur-
rent targets have been identified, and can now be evaluated
in further studies moving towards human clinical trials.
6.2 Transplantation
An alternative to promoting endogenous remyelination is
to transplant exogenous OPCs into the CNS to remyelinate.
This approach has been investigated in spinal cord injury-
induced demyelination, and transplantation of OPCs fol-
lowing contusion or irradiation of the rat spinal cord leads
to increased remyelination and functional recovery [120,
121]. Similarly, recent studies show that human neural
stem cell transplants are able to induce robust remyelina-
tion with normal compact myelin ultrastructure and orga-
nisation in dysmyelinated mice [122]. However, there are
significant hurdles associated with cell transplantation
[123]. MS is a multifocal chronic disease and would
therefore probably require cell transplantation into all areas
of demyelination throughout the course of the disease, as
evidence from experimental animal models suggests that
transplanted glial progenitor cells may have limited
migration potential [124]. Controlling the proliferation and
differentiation process of transplanted cells may also be
difficult; the cells could migrate inappropriately or prolif-
erate excessively (perhaps forming tumours), and fail to
remyelinate. Even if we surmount these problems in our
animal models, as they may not reflect the exact human
pathology, this may lead to different cell behaviour and
effect in clinical trials of transplants in humans. Patients
would need immunosuppression if the source of trans-
planted OPCs is human embryonic stem cells; however,
OPCs can now also be derived from patient-specific
induced pluripotent stem (iPS) cells (albeit slowly), and
these mature into oligodendrocytes, forming functional
myelin around axons at least in mouse brain. This may
provide an alternative to strong immune suppression [125].
However, these techniques are still being developed, and
their safety and efficacy remain unknown.
7 Discussion
While only a very few remyelination-enhancing therapies
are currently being tested in clinical trials, recent preclin-
ical research has identified many potential targets that
enhance OPC migration to the site of injury and differen-
tiation into myelinating oligodendrocytes, both of which
may improve remyelination in vivo. In addition, much
work is focusing on the underlying pathology in MS,
especially to elucidate why remyelination is inefficient in
the human condition compared with other animals. The
grouping of these targets into two classes – the pro-
migration and the pro-differentiation pathways – provides
both advantages and disadvantages. There is now a diver-
sity of targets, but how do we determine which drug to use
for which MS lesion in which patient and at what time? For
example, anti-LINGO-1 antibodies and RXR agonists may
enhance remyelination in lesions containing OPCs with
impaired differentiation, but not in OPC-deficient lesions.
Conversely, a Sema3A-neuropilin1 interaction inhibitor
may help in treating lesions with a lack of progenitor cells
only. As MS patients mostly present with a mixture of both
types of lesions, should we just treat with molecules from
both groups or could this be detrimental? Some molecules
that promote migration, e.g. PDGF, also inhibit differen-
tiation, which may be counterproductive at the wrong time.
Understanding the time course of remyelination in human
MS, which will be different from in experimental models,
will be critical here, but this is where we find another
hurdle: remyelination in humans cannot yet be reliably
measured directly. Several studies have attempted to use
MRI measures in order to quantify myelination [126–129],
but the resolution of these imaging techniques is not yet
good enough to distinguish between varying degrees of
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remyelination/demyelination and axonal damage. The
outcome of brain atrophy measured by MRI is correlated
with disease progression, but this is downstream of, and
maybe also in part unrelated to, the remyelination effect
and takes time to change. In the laboratory setting, using
experimental models of demyelination, remyelination is
quantified by counting the number of axons with a myelin
sheath and measuring the thickness of this myelin using
electron microscopy. This is the (time-consuming) gold
standard for assessing the extent of remyelination; how-
ever, it is useless for in vivo quantification and human
clinical trials. An alternative biomarker, preferably in the
serum or perhaps the CSF, will be critical to help assess
remyelination, but identifying a suitable candidate remains
a challenge. CSF neurofilament levels may represent neu-
rodegeneration in MS [130], but, although potentially
useful, this is still downstream of remyelination, and not a
direct measure of it. Furthermore, determining which MS
lesions have sufficient or few OPCs in vivo is currently
impossible.
In spite of this lack of a robust biomarker of remyeli-
nation, clinical trials studying potential pro-remyelinating
therapies are in progress, using the outcomes of MR
measures of brain atrophy, retinal nerve layer thickness
(using optical coherence tomography) and clinical dis-
ability—all surrogate markers. However, pharma are pre-
pared to embark on such costly and time-consuming trials
due to the importance of trying to find a treatment for the
unmet need of treatment to avoid progressive MS. Design
of these clinical trials raises still more problems with
regard to subject selection and timing of treatments: which
MS patients with what disease course (RRMS vs. SPMS vs.
PPMS) should be treated and when? When would we
expect to see a difference? How can we deliver the drug?
The answers to these questions are difficult and compro-
mises will be made and lessons learnt from early trials. As
we believe that endogenous remyelination is reasonably
efficient early in RRMS, perhaps pro-remyelination ther-
apy is only needed later in the relapsing-remitting stage or
at the secondary progressive stage, when disability accu-
mulates. However, we also know that neurodegeneration
occurs early and perhaps, by this time, some lesions may be
chronically demyelinated and not amenable to this therapy.
When progressive disease is established, is this the time to
initiate such therapy, or is this too little, too late? Or, by
starting such treatment early, would we inflict drugs (which
inevitably have side effects) on patients who would do
better without our intervention? Is it also wise to combine
immunomodulator and pro-remyelinating drugs? We know
that some aspects of inflammation are required for suc-
cessful remyelination, at least in part due to activation of
microglia/macrophages to both clear the debris and pro-
duce pro-regenerative factors [53, 54, 131]. The only way
to resolve these questions is to improve imaging of such
lesions, perhaps by positron emission tomography (PET)
imaging or new MR sequences. Techniques to trace OPCs
after relapses or during progressive disease in MS patients
may give insight into the time course of OPC recruitment
and differentiation and inform us when remyelination-
promoting targets may have a positive effect.
In addition to choosing the correct patients, and treating
at the most appropriate time, how long should each trial
be? We do not know the tempo of remyelination in
humans, but it is likely to be over months, and the sub-
sequent effect on protection from neurodegeneration may
only become obvious over years. Long clinical trials are
very expensive but probably currently necessary using our
current outcome measures of brain atrophy or accumula-
tion of disability.
Designing a pro-remyelinating drug from the targets
identified to be appropriate for patients is also chal-
lenging. Ideally, the drug would be oral, long-acting,
selective for remyelination in the CNS and with no other
systemic side effects. Currently licensed MS treatments
act by modulating the immune system and are therefore
not required to enter the CNS. However, compounds that
promote remyelination need to pass through the blood–
brain barrier, which complicates their design—for
example, the amount of antibody reaching the CNS when
given systemically will be low. To get around this
problem, we may consider direct delivery of potential
drug candidates into the CNS, either via the CSF or even
perhaps intra-nasally, and chemists are trying to design
ways of packaging molecules so that they cross the
blood–brain barrier more easily, thus trying to make the
treatments more effective when given systemically and
making them patient friendly.
All of these complex considerations are necessary in
order to design the best clinical trials that help us to
understand whether potential candidate drugs aid remyeli-
nation in human MS patients to provide putative treatments
that slow disease.
8 Conclusions
Remyelination-enhancing therapies for patients with MS
are not yet reality, but we believe they will reduce disease
progression and disability. Preclinical research has identi-
fied multiple targets affecting remyelination in experi-
mental animal models of demyelinating disease, and early
stage human clinical trials have started. However, these
studies need validation, careful planning due to the lack of
easy and robust biomarkers for remyelination, and time,
which is frustrating (but necessary) for patients and doctors
alike.
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